CIN: L15142RJ1991PLC006353

Date: 10th February, 2022

To, BSE Limited, Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001

(BY BSE LISTING CENTRE)

Sub: Disclosure pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Dear Sir /Ma'am,

In accordance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Un-audited Financial Results of the Company for the quarter and nine months ended on 31st December, 2021 and Limited Review Report on Un-audited Financial Results for the quarter and nine months ended on 31st December, 2021.

You are requested to kindly take the same on record.

Yours Faithfully, FOR SARDA PROTEINS LTD

For SARDA PROTEINS LTD.

iny Secretary

AMIT KUMAR MODI COMPANY SECRETARY & COMPLIANCE OFFICER M. NO.: A29371

Encl: a/a

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan) Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan) Contact No.: +91-7737822222; E Mail: sardaproteins@yahoo.com; Web: www.sardaproteins.com

SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan) Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com CIN: L15142RJ1991PLC006353

STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER 2021

| | 1 | Ouarter ended | | | Nine Months ended | | Year ended |
|-------------|---|--|--|----------------|---|--|--|
| S. No. | Particulars | 31,12,2021 30,09,2021 31,12,2020 | | | 31,12,2021 31,12,2020 | | 31.03,2021 |
| | | Un-Audited | Un-Andited | Un-Audited | Un-Audited | Un-Audited | Andited |
| L | Revenue from Operations | 274.00 | 74.58 | 46.26 | 418,34 | 1,084,40 | 1,135.99 |
| n. | Other Income | 2.93 | 2.54 | 1,65 | 7.57 | 5.72 | 8.39 |
| 111, | Total Income (1+11) | 276,93 | 77.12 | 47,91 | 425.91 | 1,090.12 | 1,144.38 |
| III. IV. | a subsequences and a constraint of the second s | 410,75 | 11.14 | 47.21 | 4601/1 | Gorder the | |
| | Expenses | | | | | | |
| | Cost of Material Consumed | 2/2.01 | 73.58 | 46,22 | 410.34 | 1,046,52 | 1,098.00 |
| | Purchase of Stock -in- Trade | 267.01 | 13.35 | 40,22 | 410,54 | 1,040,32 | 1,020.00 |
| | Changes in Inventories (Finished Goods, | | | | | | |
| | WIP, Stock-in-Trade) | | | * | 10.03 | 8.45 | 12.10 |
| | Employee Benefit Expenses | 3.48 | 2.87 | 2.99 | the back to a subscription of the back of the | | si sere as a subscription and the second differences |
| | Finance Cost | | 0.02 | | 0.02 | 0.01 | 0.14 |
| | Depreciation and Amoritsation Expenses | 0.02 | 0.02 | 0,08 | 0.06 | 0.24 | 0.05 |
| | Other expenses | 0.82 | 3.02 | 1.56 | 3.84 | 24.86 | 27.84 |
| | Total Expenses (IV) | 271.33 | 79.51 | 50,85 | 424.29 | 1,080.08 | 1,138.25 |
| V. | Profit/(Loss) before Exceptional and | | | | | | |
| | Extraordinary Items and Tax (III-IV) | 5.60 | (2.39) | (2.94) | 1.62 | 10.04 | 6.13 |
| VI. | Exceptional Items | | | | | 14 | |
| VII. | Profit/(Loss) before Tax (V-VI) | 5,60 | (2.39) | (2.94) | 1.62 | 10.04 | 6.13 |
| VIII | Tax Expense: | | A State of the second s | | | | |
| | (1) Current Tax | | | | | - | 0.95 |
| | (2) Deferred Tax | * | | | - | | 7.20 |
| IX. | Profit/(Loss) for the period from Continuing | and the second s | | | | | |
| 1.7. | | 5.60 | (2.39) | (2.94) | 1.62 | 10.04 | (2.02 |
| | Operations (VII-VIII) | 3.00 | (2.37) | (2.74) | 1.04 | 10.04 | (Linz |
| Х, | | | | | | 1000 | |
| | Profit/(Loss) from Discontinued Operations | 47 | - | | | | |
| XI. | | | 國際自然電視 | | | | |
| | Tax Expenses of Discontinued Operations | | | + | | - | |
| XII, | Profit/(Loss) from Discontinued Operations | | | | | | |
| | (after tax) (X-XI) | | * | | | | |
| XIII. | Profit/(Loss) for the Period (IX+XII) | 5.60 | (2.39) | (2.94) | 1.62 | 10.04 | (2.02 |
| XIV | Other Comprehensive Income | and the second second second | | | | | |
| | A (i) Items will not be reclassified to Profit | 的原则有限的原则 | | | | | |
| | or Loss. | | | and the second | - | | - |
| | (ii) Income Tax relating to items that will | and the second | as brack the | | | | |
| | not be reclassified to Profit or Loss | | | | 1999 - S. | | |
| | B (i) Items will be reclassified to Profit or | | | | | S. S | |
| | Loss | | - | | Sector Contents | - | |
| | (ii) Income Tax relating to items that will | | | | | | |
| | be reclassified to Profit or Loss | | Charles La Ch | | | | |
| XV. | | | a and a second solution of the second second | | | | |
| | Total Comprehensive Income for the period | | | | | | |
| | (XIII+XIV)(Comprising Profit (Loss) and | | | | | | |
| | other Comprehensive Income for the period) | 5.60 | (2.39) | (2,94) | 1.62 | 10.04 | (2.02 |
| XVI. | Paid Up Equity Share Capital, Equity Shares | | Animal | X7.5 M | | | |
| | Of Face Value Rs. 10 each | 172.59 | 172.59 | 172,59 | 172.59 | 172.59 | 172,59 |
| VUH | Earnings per Equity Share | 114.17 | A Plants | | | a freeder | |
| XVII. | in a second s | 0,32 | (0,14) | (0.17) | 0,09 | 0.58 | (0.12 |
| | (1) Basic | 0,32 | (0.14) | (0.17) | 0.09 | 0.58 | (0.12 |
| | (2) Diluted | V.31 | [57, 1 4] | (0.17) | 0.03 | 0,,0 | |

Notes:

1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 10th February 2022.

2 Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.

3. Segment Results as per AS is not applicable as dealing in only one segment i.e. * Agro Products*.

4. No Investor Complaints were received during the quarter ended 31-Dec-2021 nor any pending as on 01-Jan-2022. on behalf of the Board

-WEVAWS Place: Japur Charteres Date : 10-Feb-2022

Deepak Data (DIN: 01672415) Managing Director

Sarda Proteins Ltd

UDIN: - 22072054 ABDW BN 6301



Khetawat Agarwal & Co. Chartered Accountants

Limited Review Report Unaudited Standalone Quarterly and Half Year Results

To The Board of Directors Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter and nine months ended on 31st December, 2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khetawat Agarwal & Co. wal & **Chartered Accountants** FRN: 003960C

M.L. Agarwal Partner M. No.: 072854 UDIN: 22072854ABDWBN6301

Place : Jaipur Date : 10.02.2022